Immuron (ANWA) AI Stock Analysis

Top Page

Immuron

(Frankfurt:ANWA)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Commercialization ScaleThe multi-year increase in revenue demonstrates that Immuron has moved beyond a purely developmental profile and established commercial traction. A larger revenue base can support broader distribution, improve operating leverage, and provide a platform for continued growth in gastrointestinal health products.

Negative Factors

Persistent Operating LossesImmuron has not yet converted its commercial activity and gross margin into profitability, with substantial net and operating losses still reported in 2026. Continued losses can delay self-funding, weaken returns on capital, and require management to prioritize financing over expansion or pipeline investment.

Immuron (ANWA) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 5.67M
Dividend Yield: ―
Average Volume (3M): 6,000
Price to Earnings (P/E): -3.1
Beta (1Y): -0.00
Revenue Growth: ―
EPS Growth: ―
Country: Germany
Employees: 7
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Immuron Business Overview & Revenue Model

Company Description

Immuron Limited is a biopharmaceutical company focused on the discovery, development, and global commercialization of polyclonal antibodies, with operations spanning Australia, the United States, and other international markets. The company's activit...

Immuron Risk Analysis

Immuron disclosed 62 risk factors in its most recent earnings report. Immuron reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

2 New Risks

1.If we fail to comply with the rules under the Sarbanes-Oxley Act of 2002 related to accounting controls and procedures in the future, or, if we discover additional material weaknesses and other deficiencies in our internal control and accounting procedures, the price of our ordinary shares and ADSs could decline significantly and raising capital could be more difficult.Q2, 2024

2.A material breach in security relating to the Company's information systems and regulation related to such breaches, cyber-attacks, or other disruptions could adversely affect the Company, expose us to liability and affect our business and reputation.Q2, 2024

Immuron Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:ANWA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LPCN	51Neutral	$11.87M	-0.77	-64.75%	―	-62.70%	-121.27%
CANF	40Underperform	$5.08M	-0.24	-182.88%	―	―	―
BIVI	38Underperform	$12.20M	-0.45	-126.02%	―	―	78.51%

* Healthcare Sector Average

Performance Comparison

DE:ANWA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:ANWA	Immuron	0.78	-0.85	-52.16%
CANF	Can-Fite BioPharma Ltd	1.62	-6.62	-80.33%
LPCN	Lipocine Inc	1.44	-1.21	-45.66%
BIVI	Biovie Inc.	1.43	-0.28	-16.37%
ASBP	Aspire Biopharma Holdings, Inc.	8.11	-425.93	-98.13%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Immuron AI Stock Analysis